Vanguard Group
CTOR

Vanguard Group’s Citius Oncology CTOR Stock Holding History

Vanguard Group’s Portfolio CTOR Stock Details CTOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$597K Buy
596,997
+416,829
+231% +$598K ﹤0.01% 3907
2025
Q3 		$366K Buy
+180,168
New +$390K ﹤0.01% 4017

Other funds holding CTOR

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OAC
OMERS Administration Corp Toronto, Ontario, Canada $15.6B AUM 24.73% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group's CTOR Position: Q4 2025 in Review

Vanguard Group increased its Citius Oncology (CTOR) stake by 231% in Q4 2025, buying an estimated $598K and bringing the position to 596,997 shares worth $597K. The position accounts for ﹤0.01% of the portfolio, ranked #3907.

Vanguard Group first reported a position in CTOR in Q3 2025 and has held it in 2 quarters since. 18 funds tracked by Wall St. Rank hold CTOR as of Q4 2025.

  • Vanguard Group held 596,997 shares of Citius Oncology worth $597K as of Q4 2025.
  • Vanguard Group bought 416,829 Citius Oncology shares in Q4 2025, an estimated $598K.
  • Citius Oncology made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3907 holding.
  • Vanguard Group first reported a position in Citius Oncology in Q3 2025 and has held it in 2 quarters since.
  • 18 funds tracked by Wall St. Rank held Citius Oncology as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.